|
|
|
|
|
UCB has a rich heritage in epilepsy with over 30 years of experience in the research and development
of antiseizure medications. As a company with a long-term commitment to epilepsy research, our
goal is to address unmet medical needs. Our scientists are proud to contribute to advances in the
understanding of epilepsy and its treatment. We partner and create super-networks with world-leading
scientists and clinicians in academic institutions, pharmaceutical companies, and other organizations
who share our goals. At UCB, we are inspired by patients and driven by science in our commitment to
support patients with epilepsy.
|
|
|
Earlier Identification and Treatment of Patients with a Developmental
and Epileptic Encephalopathy (DEE): Taking a Close Look at
Lennox-Gastaut Syndrome (LGS)
|
|
Presented by Heidi Henninger, MD, FAAN; Michael Chez, MD, FAAN, FAES; David Burdette, MD, FACNS;
and Tracy Dixon-Salazar, PhD
|
|
Saturday, April 5 • 11:45 am – 12:45 pm PT
|
|
San Diego Convention Center, 6B • San Diego, CA
|
|
You are invited to join UCB for a lunchtime Industry Therapeutic Update where you will learn from a panel of expert
epileptologists on how to identify patients with LGS in your practice, when to refer, and current treatment developments.
In addition, hear unique perspectives from a patient advocate and caregiver on the burden of LGS and the potential
impact of delayed diagnosis and treatment.
|
|
|
| |
Rethinking Seizure Emergencies: Expert Perspectives
on a New Paradigm
|
|
Presented by Kamil Detyniecki, MD and Sheryl Haut, MD
|
|
Monday, April 7 • 6:00 – 8:00 pm PT
|
|
San Diego Ballroom A, Marriott Marquis • San Diego, CA
|
|
You are invited to join UCB for a dinner program where experts will discuss the latest thinking and developments
around seizure emergencies, including a new paradigm for rapid and early seizure termination (REST) and acute cluster
termination (ACT).
|
|
|
|
|
|
|
UCB has various scientific posters available for review at the AAN Annual Meeting. Please refer to your official program for details.
|
|
|
|
|
|
At UCB, patients are at the heart of all we do. We are excited to connect with you in person at AAN 2025
in San Diego and look forward to sharing important updates from UCB’s epilepsy portfolio.
|
|
|
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the
views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual
Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication,
research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
|
|
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not appropriate, and associated expenses will not be reimbursed. Certain state and federal requirements place restrictions on and/or require disclosure of items UCB provides to healthcare professionals, including meals and refreshments. UCB is committed to complying with all legal requirements.
|
| |
|
©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved.
US-FA-2500194
|
| If you no longer wish to receive emails from us, click here to unsubscribe. |
|
|
